Page 1832 - Hematology_ Basic Principles and Practice ( PDFDrive )

1632.e2 Part X Transplantation

reactivity, and tolerance after bone marrow transplantation. Blood 66. Bachar-Lustig E, Li HW, Gur H, et al: Induction of donor-type chi-
77(11):2515–2523, 1991. merism and transplantation tolerance across major histocompatibility
+
46. Xun CQ, Thompson JS, Jennings CD, et al: Effect of total body barriers in sublethally irradiated mice by Sca-1 Lin− bone marrow
irradiation, busulfan-cyclophosphamide, or cyclophosphamide condi- progenitor cells: synergism with non-alloreactive (host × donor)F 1 T
tioning on inflammatory cytokine release and development of acute cells. Blood 94(9):3212–3221, 1999.
and chronic graft-versus-host disease in H-2 incompatible transplanted 67. Miller RG: An immunological suppressor cell inactivating cytotoxic
SCID mice. Blood 83:2360–2367, 1994. T-lymphocyte precursor cells recognizing it. Nature 287(5782):544–
47. Walker I, Shehata N, Cantin G, et al: Canadian multicenter pilot 546, 1980.
trial of haploidentical donor transplantation. Blood Cells Mol Dis 68. Fink PJ, Weissman IL, Bevan MJ: Haplotype-specific suppression of
33(3):222–226, 2004. cytotoxic T cell induction by antigen inappropriately presented on T
48. Waller EK, Langston AA, Lonial S, et al: Pharmacokinetics and phar- cells. J Exp Med 157(1):141–154, 1983.
macodynamics of anti-thymocyte globulin in recipients of partially 69. Anasetti C, Beatty PG, Storb R, et al: Effect of HLA incompatibility
HLA-matched blood hematopoietic progenitor cell transplantation. on graft-versus-host disease, relapse, and survival after marrow trans-
Biol Blood Marrow Transplant 9(7):460–471, 2003. plantation for patients with leukemia or lymphoma. Hum Immunol
49. Mattsson J, Ringdén O, Storb R: Graft failure after allogeneic 29(2):79–91, 1990.
hematopoietic cell transplantation. Biol Blood Marrow Transplant 14(1 70. Beatty PG, Clift RA, Mickelson EM, et al: Marrow transplantation
Suppl):165, 2008. from related donors other than HLA-identical siblings. N Engl J Med
50. Kernan NA, Flomenberg N, Dupont B, et al: Graft rejection in 313(13):765–771, 1985.
recipients of T-cell-depleted HLA-nonidentical marrow transplants 71. Teshima T, Matsuo K, Matsue K, et al: Impact of human leucocyte
for leukemia: identification of host-derived antidonor allocytotoxic T antigen mismatch on graft-versus-host disease and graft failure after
lymphocytes. Transplantation 43(6):842–847, 1987. reduced intensity conditioning allogeneic haematopoietic stem cell
51. Kiessling R, Hochman PS, Haller O: Evidence for a similar or common transplantation from related donors. Br J Haematol 130(4):575–587,
mechanism for natural killer cell activity and resistance to hemopoietic 2005.
grafts. Eur J Immunol 7(9):655–663, 1977. 72. Saliba RM, de Lima M, Giralt S, et al: Hyperacute GVHD: risk factors,
52. Ciurea SO, de Lima M, Cano P, et al: High risk of graft failure in outcomes, and clinical implications. Blood 109(7):2751–2758, 2007.
patients with anti-HLA antibodies undergoing haploidentical stem-cell 73. Berger M, Figari O, Bruno B, et al: Lymphocyte subsets recovery
+
transplantation. Transplantation 88:1019, 2009. following allogeneic bone marrow transplantation (BMT): CD4
53. Ciurea SO, Thall PF, Milton DR, et al: Complement-binding donor- cell count and transplant-related mortality. Bone Marrow Transplant
specific anti-HLA antibodies and risk of primary graft failure in 41(1):55–62, 2008.
hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 74. Eyrich M, Lang P, Lal S, et al: A prospective analysis of the pattern of
21(8):1392–1398, 2015. immune reconstitution in a paediatric cohort following transplantation
54. Taylor PA, Ehrhardt MJ, Roforth MM, et al: Preformed antibody, not of positively selected human leucocyte antigen-disparate haematopoietic
primed T cells, is the initial and major barrier to bone marrow engraft- stem cells from parental donors. Br J Haematol 114(2):422–432, 2001.
ment in allosensitized recipients. Blood 109(3):1307–1315, 2007. 75. Haddad E, Landais P, Friedrich W, et al: Long-term immune reconstitu-
55. Ottinger HD, Rebmann V, Pfeiffer KA, et al: Positive serum crossmatch tion and outcome after HLA-nonidentical T-cell-depleted bone marrow
as predictor for graft failure in HLA-mismatched allogeneic blood stem transplantation for severe combined immunodeficiency: a European
cell transplantation. Transplantation 73(8):1280–1285, 2002. retrospective study of 116 patients. Blood 91(10):3646–3653, 1998.
56. Zachary AA, Sholander JT, Houp JA, et al: Using real data for a virtual 76. Noel DR, Witherspoon RP, Storb R, et al: Does graft-versus-host disease
crossmatch. Hum Immunol 70(8):574–579, 2009. influence the tempo of immunologic recovery after allogeneic human
57. Braun N, Faul C, Wernet D, et al: Successful transplantation of marrow transplantation? An observation on 56 long-term survivors.
+
highly selected CD34 peripheral blood stem cells in a HLA-sensitized Blood 51(6):1087–1105, 1978.
patient treated with immunoadsorption onto protein A. Transplantation 77. Weinberg K, Blazar BR, Wagner JE, et al: Factors affecting thymic
69(8):1742–1744, 2000. function after allogeneic hematopoietic stem cell transplantation. Blood
58. Woolfrey A, Anasetti C: Allogeneic hematopoietic stem-cell engraft- 97(5):1458–1466, 2001.
ment and graft failure. Pediatr Transplant 3(Suppl 1):35, 1999. 78. Bethge WA, Faul C, Bornhäuser M, et al: Haploidentical allogeneic
59. O’Reilly RJ, Keever C, Kernan NA, et al: HLA nonidentical T cell hematopoietic cell transplantation in adults using CD3/CD19 deple-
depleted marrow transplants: a comparison of results in patients tion and reduced intensity conditioning: an update. Blood Cells Mol Dis
treated for leukemia and severe combined immunodeficiency disease. 40(1):13–19, 2008.
Transplant Proc 19(6 Suppl 7):55–60, 1987. 79. Davies JK, Gribben JG, Brennan LL, et al: Outcome of alloanergized
60. Bachar-Lustig E, Rachamim N, Li HW, et al: Megadose of T cell- haploidentical bone marrow transplantation after ex vivo costimulatory
depleted bone marrow overcomes MHC barriers in sublethally irradi- blockade: results of two phase I studies. Blood 112:2232, 2008.
ated mice. Nat Med 1(12):1268–1273, 1995. 80. Rizzieri DA, Koh LP, Long GD, et al: Partially matched, nonmy-
61. Sykes M, Szot GL, Swenson KA, et al: Induction of high levels of eloablative allogeneic transplantation: clinical outcomes and immune
allogeneic hematopoietic reconstitution and donor-specific tolerance reconstitution. J Clin Oncol 25(6):690–697, 2007.
without myelosuppressive conditioning. Nat Med 3(7):783–787, 1997. 81. Terenzi A, Aristei C, Aversa F, et al: Efficacy of fludarabine as an
62. Aversa F, Tabilio A, Terenzi A, et al: Successful engraftment of immunosuppressor for bone marrow transplantation conditioning:
T-cell-depleted haploidentical “three-loci” incompatible transplants preliminary results. Transplant Proc 28(6):3101, 1996.
in leukemia patients by addition of recombinant human granulocyte 82. Pan L, Delmonte J, Jr, Jalonen CK, et al: Pretreatment of donor mice
colony-stimulating factor-mobilized peripheral blood progenitor cells with granulocyte colony-stimulating factor polarizes donor T lym-
to bone marrow inoculum. Blood 84(11):3948–3955, 1994. phocytes toward type-2 cytokine production and reduces severity of
63. Reisner Y, Martelli MF: Bone marrow transplantation across HLA experimental graft-versus-host disease. Blood 86(12):4422–4429, 1995.
barriers by increasing the number of transplanted cells. Immunol Today 83. Volpi I, Perruccio K, Tosti A, et al: Postgrafting administration of gran-
16(9):437–440, 1995. ulocyte colony-stimulating factor impairs functional immune recovery
+
64. Reich-Zeliger S, Zhao Y, Krauthgamer R, et al: Anti-third party CD8 in recipients of human leukocyte antigen haplotype-mismatched
CTLs as potent veto cells: coexpression of CD8 and FasL is a prereq- hematopoietic transplants. Blood 97(8):2514–2521, 2001.
uisite. Immunity 13(4):507–515, 2000. 84. Or-Geva N, Reisner Y: The evolution of T-cell depletion in haploidenti-
65. Reisner Y, Gur H, Reich-Zeliger S, et al: Hematopoietic stem cell cal stem-cell transplantation. Br J Haematol 172(5):667–684, 2016.
transplantation across major genetic barriers: tolerance induction 85. Waller EK, Giver CR, Rosenthal H, et al: Facilitating T-cell immune
by megadose CD34 cells and other veto cells. Ann N Y Acad Sci reconstitution after haploidentical transplantation in adults. Blood Cells
996:72–79, 2003. Mol Dis 33(3):233–237, 2004.